Geron to Present at Needham Virtual Healthcare Conference
08 avr. 2020 16h30 HE
|
Geron Corporation
MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Geron Provides COVID-19 Related Business Update
02 avr. 2020 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical development biopharmaceutical company, today announced an update to information from...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 nov. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of...
Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events
06 nov. 2019 16h10 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as...
Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
06 nov. 2019 09h18 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor,...
Geron to Announce Third Quarter Financial Results on November 6, 2019
31 oct. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2019 financial results after the market closes on...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 oct. 2019 16h10 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of...
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
10 oct. 2019 17h30 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate...
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
30 sept. 2019 16h19 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation...
Geron to Present at 2019 Cantor Global Healthcare Conference
26 sept. 2019 16h18 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...